DARE-19 Phase III Collaboration Between AstraZeneca, Saint Luke’s Mid America Heart Institute and George Clinical Shows Treatment’s Well-Established Safety Profile was Consistent in Patients with COVID-19
OVERLAND PARK, KS, July 29 (Korea Bizwire) — The findings of DARE-19, a double-blind, placebo-controlled Phase III trial examining Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19, have been published in The Lancet Diabetes & Endocrinology. The study was a collaboration of George Clinical, a global scientifically-backed clinical research organization and Saint Luke’s Mid [...]
